Sacituzumab Govitecan as a Treatment Option for Patients with metastatic triple-negative Breast Cancer and impending Liver Failure: two Case Reports

被引：0
|
作者：
Wolf, E. E. [1 ]
Agabejli, S. [1 ]
Wimberger, P. [1 ]
Link, T. [1 ]
机构：
[1] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Inst Abt Gynakol & Geburtshilfe, Dresden, Germany
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2023年 / 83卷 / 06期
关键词：
D O I：
10.1055/s-0043-1769875
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
66
引用
收藏
页码：E34 / E34
页数：1
相关论文
共 50 条
  • [21] The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer
    Michaleas, S.
    Oliver, A. Moreno
    Mueller-Berghaus, J.
    Sarac, S. B.
    van der Elst, M. E.
    Mueller-Egert, S.
    Zander, H.
    Enzmann, H.
    Pignatti, F.
    ESMO OPEN, 2022, 7 (03)
  • [22] Metastatic triple-negative breast cancer (mTNBC) first-in-class therapy with sacituzumab govitecan
    Schoellmann, Claudia
    BREAST CARE, 2022, 17 (01)
  • [23] Exposure-Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple-Negative Breast Cancer
    Sathe, Abhishek G.
    Diderichsen, Paul M.
    Fauchet, Floris
    Phan, See-Chun
    Girish, Sandhya
    Othman, Ahmed A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025, 117 (02) : 570 - 578
  • [24] A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer
    Bardia, Aditya
    Hurvitz, Sara A.
    Rugo, Hope S.
    Brufsky, Adam
    Cortes, Javier
    Loibl, Sibylle
    Piccart, M.
    Cowden, Janice
    Spears, Patty
    Carey, Lisa A.
    FUTURE ONCOLOGY, 2021, 17 (30) : 3911 - 3924
  • [25] Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study
    Carrion-Madronal, Isabel Maria
    Diaz-Acedo, Rocio
    Lora-Escobar, Santiago Jose
    Naranjo-Llamas, Eloisa
    Jaramillo-Ruiz, Didiana
    Artacho-Criado, Silvia
    Prado-Mel, Elena
    FUTURE ONCOLOGY, 2024, 20 (33) : 2565 - 2572
  • [26] Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
    Weiss, Jennifer
    Glode, Ashley
    Messersmith, Wells A.
    Diamond, Jennifer
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (08) : 673 - 679
  • [27] Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
    O'Shaughnessy, Joyce
    Brufsky, Adam
    Rugo, Hope S.
    Tolaney, Sara M.
    Punie, Kevin
    Sardesai, Sagar
    Hamilton, Erika
    Loirat, Delphine
    Traina, Tiffany
    Leon-Ferre, Roberto
    Hurvitz, Sara A.
    Kalinsky, Kevin
    Bardia, Aditya
    Henry, Stephanie
    Mayer, Ingrid
    Zhu, Yanni
    Phan, See
    Cortes, Javier
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 195 (02) : 127 - 139
  • [28] Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
    Joyce O’Shaughnessy
    Adam Brufsky
    Hope S. Rugo
    Sara M. Tolaney
    Kevin Punie
    Sagar Sardesai
    Erika Hamilton
    Delphine Loirat
    Tiffany Traina
    Roberto Leon-Ferre
    Sara A. Hurvitz
    Kevin Kalinsky
    Aditya Bardia
    Stephanie Henry
    Ingrid Mayer
    Yanni Zhu
    See Phan
    Javier Cortés
    Breast Cancer Research and Treatment, 2022, 195 : 127 - 139
  • [29] Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back
    Rossi, Valentina
    Turati, Alessandra
    Rosato, Antonio
    Carpanese, Debora
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [30] Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer
    Seligson, John M.
    Patron, Alexandra M.
    Berger, Michael J.
    Harvey, R. Donald
    Seligson, Nathan D.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (07) : 921 - 931
12345